We demonstrated that the combination synergistically decreases the survival of HR+ breast cancer cells harboring PIK3CA mutations or PTEN loss and elicits robust anti-tumor activity in PIK3CA-mutant PDX models resistant to alpelisib and/or palbociclib combined with endocrine therapy. This evidence concerns the gene PIK3CA and breast carcinoma.